CASIs ENMD-2076 gets FDA Orphan Medication designation for HCC treatment CASI Pharmaceuticals.

Dr. Ken Ren, Chief Executive Officer of CASI, commented, We are happy with the Orphan Medication designation since it confirms our belief in the versatility of ENMD-2076 as a promising treatment for HCC, and for other tumor types that we are evaluating in the clinic currently. Orphan drug status enhances the commercial value of ENMD-2076 to take care of HCC also, a disease which is tough to take care of. We are finalizing our next steps for ENMD-2076 in HCC and/or in fibrolamellar carcinoma, a subset of HCC and for which there is no treatment available and appearance forward to advancing our general development plan for ENMD-2076.If level of resistance did take place in the general population, it would not be detected by current diagnostic procedures. Related StoriesCrucial modification in single DNA base predisposes children to intense form of cancerNew analysis uncovers antibiotic prescription trends across EnglandCancer DNA in individual's bloodstream may help deliver personalized treatment for liver cancer’As yet a person treated with antibiotics with a reoccurring infection of C. Trachomatis was assumed to have been re-contaminated’ says Dr Nicholas Thomson, senior writer from the Wellcome Trust Sanger Institute.